What's Happening?
Altasciences, a company specializing in integrated drug development solutions, has announced a strategic partnership with Certara, a leader in model-informed drug development (MIDD). This collaboration aims to accelerate early-phase drug development programs
by integrating Certara's biosimulation technology and strategic drug development services into Altasciences' Acceleration Platform. The partnership seeks to address common challenges in drug development, such as toxicity and poor pharmacokinetics, by using a model-informed approach to improve study designs and dosing strategies. This integration is expected to enhance decision-making processes, allowing for more efficient and informed go/no-go decisions in drug development.
Why It's Important?
The partnership between Altasciences and Certara is significant as it aligns with the FDA's push for more adaptive, data-driven, and real-time drug development approaches. By embedding modeling insights into the drug development process, the collaboration aims to reduce uncertainty and improve the success rate of preclinical drug candidates reaching human trials. This could lead to faster development of new therapies, benefiting biotech sponsors, investors, and ultimately patients. The integration of these advanced modeling capabilities is expected to streamline the drug development process, potentially reducing costs and time to market for new drugs.
What's Next?
As Altasciences and Certara implement their integrated approach, the industry may see a shift towards more model-informed drug development practices. This could influence other companies to adopt similar strategies, potentially leading to broader changes in how early drug development is conducted. The success of this partnership could also prompt further collaborations between technology providers and drug development companies, enhancing innovation and efficiency in the pharmaceutical industry.
